Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Nephrotic Syndrome I : Introduction01:24

Nephrotic Syndrome I : Introduction

457
Nephrotic Syndrome is a chronic kidney disorder defined by clinical findings such as severe proteinuria, hypoalbuminemia, hyperlipidemia, and edema. These symptoms result from damage to the glomeruli, the kidney’s filtering units, increasing their permeability to proteins.Definition and Meaning:Proteinuria, defined as the loss of more than 3.5 grams of protein per day in adults, is a crucial feature of nephrotic syndrome. This condition is often accompanied by edema, the accumulation of...
457
Acute Kidney Injury II: Pathophysiology01:29

Acute Kidney Injury II: Pathophysiology

834
Acute kidney injury (AKI) causes are categorized into three primary categories based on the location of the injury: prerenal, intrarenal (or intrinsic), and postrenal causes. This classification guides clinical management and illustrates how different pathways can impair kidney function.Etiology and Pathophysiology of Acute Kidney Injury1. Prerenal causesEtiology: Prerenal Acute Kidney Injury, the most common type, occurs when reduced blood flow to the kidneys decreases filtration capacity...
834
Chronic Kidney Disease III: Interprofessional Care01:28

Chronic Kidney Disease III: Interprofessional Care

316
Chronic kidney disease (CKD) requires collaborative and comprehensive management. CKD progresses through stages and can lead to end-stage kidney disease (ESKD) if untreated. Interprofessional collaboration and patient education are crucial, enabling patients to manage their health and improve their quality of life.Diagnostic approach for chronic kidney diseaseThe diagnosis of CKD primarily focuses on the glomerular filtration rate (GFR), which assesses kidney function by measuring how well...
316
Nephrotic Syndrome III : Nursing Management01:24

Nephrotic Syndrome III : Nursing Management

266
Nursing management for nephrotic syndrome adapts as the disease progresses, with strategies evolving to address advancing symptoms and complications.Early-Stage Management In the early stages, nursing interventions for nephrotic syndrome resemble those used in managing acute glomerulonephritis, focusing on symptom monitoring, fluid balance, and managing mild to moderate edema.Vital Signs: Regularly monitor blood pressure, pulse, respiratory rate, and temperature to promptly identify...
266
Acute Kidney Injury IV: Diagnostic Studies and Prevention01:30

Acute Kidney Injury IV: Diagnostic Studies and Prevention

238
Accurate diagnosis and effective prevention are critical in managing Acute Kidney Injury (AKI), which is linked to high mortality rates ranging from 10% to 80%. Timely recognition of at-risk patients and careful monitoring can significantly reduce the likelihood of kidney damage.Diagnostic Assessments:The diagnostic process starts with a comprehensive medical history to identify prerenal, intrarenal, and postrenal causes.Prerenal causes, such as dehydration, hypotension, or blood loss, should...
238
Nephrotic Syndrome II : Assessment and Medical Management01:26

Nephrotic Syndrome II : Assessment and Medical Management

177
IntroductionNephrotic syndrome is a kidney disorder marked by excessive protein loss in the urine, leading to various systemic complications. This condition often results from damage to the glomeruli—the kidney's filtering units—causing proteinuria, low blood protein levels, and fluid retention. Understanding the assessment, diagnosis, and management of nephrotic syndrome is essential for effective treatment and prevention of further kidney damage.AssessmentPatient History: Document...
177

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

New Horizons in IgA Nephropathy: Approach to Current and Emerging Therapies.

Cureus·2026
Same author

Is It Time to Consider Population-Based Urine Dipstick Screening for Early Detection of Kidney Disease?

Kidney international reports·2026
Same author

Prognostic value of a composite histologic score in glomerular diseases: a 10-year single center cohort study.

BMC nephrology·2026
Same author

Nephrotoxicity of conventional chemotherapeutics: part 1-platinum compounds and antimetabolite agents.

Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association·2025
Same author

Nephrotoxicity of conventional chemotherapeutics: part II-non-platinum agents and miscellaneous nephrotoxic drugs.

Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association·2025
Same author

Case Report: Copper sulphate related hemophagocytosis with lymphohistiocytosis.

F1000Research·2024

Related Experiment Video

Updated: Jan 7, 2026

Detection of MicroRNA Expression in the Kidneys of Immunoglobulin A Nephropathic Mice
05:39

Detection of MicroRNA Expression in the Kidneys of Immunoglobulin A Nephropathic Mice

Published on: July 8, 2020

2.1K

The Immunoglobulin A Nephropathy Renaissance: From Pathogenesis to Personalized Therapy.

Samyuktha Srinivas1, Sai Kumar Madhavaram2, Sarah A Bhanushali3

  • 1General Medicine, Manipal Academy of Higher Education, Manipal, IND.

Cureus
|December 30, 2025
PubMed
Summary

Immunoglobulin A nephropathy (IgAN) management is evolving beyond supportive care. New biomarkers and targeted therapies offer improved risk stratification and personalized treatment for better long-term kidney outcomes.

Keywords:
biomarkersegfr declinegalactose-deficient iga1hematuriaiga nephropathymest-c scoreproteinuriarisk stratification

More Related Videos

Author Spotlight: Investigating the Potential of Chinese Herbal Medicinal Active Dioscin in Treating IgA Nephropathy
14:18

Author Spotlight: Investigating the Potential of Chinese Herbal Medicinal Active Dioscin in Treating IgA Nephropathy

Published on: October 13, 2023

2.2K
Analyses of Proteinuria, Renal Infiltration of Leukocytes, and Renal Deposition of Proteins in Lupus-prone MRL/lpr Mice
09:43

Analyses of Proteinuria, Renal Infiltration of Leukocytes, and Renal Deposition of Proteins in Lupus-prone MRL/lpr Mice

Published on: June 8, 2022

3.4K

Related Experiment Videos

Last Updated: Jan 7, 2026

Detection of MicroRNA Expression in the Kidneys of Immunoglobulin A Nephropathic Mice
05:39

Detection of MicroRNA Expression in the Kidneys of Immunoglobulin A Nephropathic Mice

Published on: July 8, 2020

2.1K
Author Spotlight: Investigating the Potential of Chinese Herbal Medicinal Active Dioscin in Treating IgA Nephropathy
14:18

Author Spotlight: Investigating the Potential of Chinese Herbal Medicinal Active Dioscin in Treating IgA Nephropathy

Published on: October 13, 2023

2.2K
Analyses of Proteinuria, Renal Infiltration of Leukocytes, and Renal Deposition of Proteins in Lupus-prone MRL/lpr Mice
09:43

Analyses of Proteinuria, Renal Infiltration of Leukocytes, and Renal Deposition of Proteins in Lupus-prone MRL/lpr Mice

Published on: June 8, 2022

3.4K

Area of Science:

  • Nephrology
  • Immunology
  • Genetics

Background:

  • Immunoglobulin A nephropathy (IgAN) is the most common cause of glomerulonephritis and chronic kidney disease globally.
  • Clinical presentation varies from microscopic hematuria to nephrotic syndrome and kidney failure.
  • Understanding IgAN pathogenesis and ethnic variations drives a shift towards targeted therapies.

Purpose of the Study:

  • To summarize current IgAN management paradigms.
  • To focus on evolving pathophysiology, biomarkers, risk stratification, and emerging targeted therapies.
  • To highlight strategies for personalized management and improved renal outcomes.

Main Methods:

  • Narrative review synthesizing recent literature on IgAN.
  • Analysis of traditional and emerging biomarkers (proteinuria, eGFR, MEST-C features, complement products, etc.).
  • Evaluation of novel therapeutic approaches targeting mucosal immunity, B-cell signaling, and complement pathways.

Main Results:

  • Emerging biomarkers aid in risk stratification for IgAN.
  • Novel therapies target specific pathways in IgAN pathogenesis.
  • Pharmacologic agents like SGLT2 inhibitors show promise in IgAN treatment.

Conclusions:

  • Advances in biomarkers and targeted therapies enhance personalized IgAN management.
  • Optimizing treatment strategies beyond supportive care is crucial for long-term renal health.
  • Contemporary management of IgAN benefits from integrating new diagnostic and therapeutic approaches.